본문 바로가기
KERD
논문KCI 등재

신생아 저산소 허혈 뇌증의 약물 치료적 접근

Pharmacological Approaches in Newborn Infants with Hypoxic Ischemic Encephalopathy

김행미
대한신생아학회 (THE KOREAN SOCIETY OF NEONATOLOGY)|2013.08|Neonatal medicine|제20권 제3호|pp. 333-340

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

InfantNewbornIschemiaHypoxiaPharmacological

초록

Despite marked improvements in perinatal practice, neonatal hypoxic-ischemic encephalopathy (HIE) remains one of the major causes of acute mortality and chronic neurologic disability in infants and children. Several new therapeutic approaches aiming at this condition have been used in the last decade, including therapeutic hypothermia and many pharmacological agents. Therapeutic hypothermia remarkably reduces death and neurological impairment, and has therefore rapidly become the standard therapy for full-term newborn infants with moderate-to-severe HIE. However, despite these promising outcomes of therapeutic hypothermia, approximately 50% of the infants treated with hypothermia have an adverse outcome. Therefore, there exists an urgent need for other treatment options. A mechanistically driven approach to HIE has resulted in the development of many drugs that are potent antagonists of specific steps in cascades of molecular reactions in HI injury. This review provides an overview of promising pharmacological approaches of neuroprotection that may be used in clinical practice. Although several drugs have been found to be effective in preclinical evaluations, such antagonists have been ineffective in human trials. Failure has been attributed to many factors such as the complex pathology of HIE in neonates, the inevitable delays in initiation of therapy in clinical practice, and the side effects of the drugs. Moreover, many of these drugs interfere with only one step of the cascades, while multiple biochemical cascades are put in motion simultaneously. Therefore, neuroprotective strategies such as hypothermia have to deal with multiple cascades. Research is now being focused on drugs that may act synergistically or additively with hypothermia, with the hope that combination therapy might augment neuroprotection.

Abstract

Despite marked improvements in perinatal practice, neonatal hypoxic-ischemic encephalopathy (HIE) remains one of the major causes of acute mortality and chronic neurologic disability in infants and children. Several new therapeutic approaches aiming at this condition have been used in the last decade, including therapeutic hypothermia and many pharmacological agents. Therapeutic hypothermia remarkably reduces death and neurological impairment, and has therefore rapidly become the standard therapy for full-term newborn infants with moderate-to-severe HIE. However, despite these promising outcomes of therapeutic hypothermia, approximately 50% of the infants treated with hypothermia have an adverse outcome. Therefore, there exists an urgent need for other treatment options. A mechanistically driven approach to HIE has resulted in the development of many drugs that are potent antagonists of specific steps in cascades of molecular reactions in HI injury. This review provides an overview of promising pharmacological approaches of neuroprotection that may be used in clinical practice. Although several drugs have been found to be effective in preclinical evaluations, such antagonists have been ineffective in human trials. Failure has been attributed to many factors such as the complex pathology of HIE in neonates, the inevitable delays in initiation of therapy in clinical practice, and the side effects of the drugs. Moreover, many of these drugs interfere with only one step of the cascades, while multiple biochemical cascades are put in motion simultaneously. Therefore, neuroprotective strategies such as hypothermia have to deal with multiple cascades. Research is now being focused on drugs that may act synergistically or additively with hypothermia, with the hope that combination therapy might augment neuroprotection.

참고문헌 (91)

  1. Perlman JM, "Neonatal resuscitation: 2010 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations", Pediatrics, 126, pp.e1319~e1344 (2010)
  2. 장미영, "신생아 저산소성 허혈성 뇌증의 저체온 치료", Neonatal medicine, 20(1), pp.2~11 (2013), 대한신생아학회
  3. Jacobs SE, "Cooling for newborns with hypoxic ischaemic encephalopathy", Cochrane Database Syst Rev, 1, pp.CD003311~ (2013)
  4. Cilio MR, "Synergistic neuroprotective therapies with hypothermia", Semin Fetal Neonatal Med, 15, pp.293~298 (2010)
  5. 곽수희, "열 전처지가 신생쥐의 허혈성 저산소성 뇌손상에 미치는 영향", Neonatal medicine, 15(1), pp.32~37 (2008), 대한신생아학회
  6. Peng B, "Remote ischemic postconditioning protects the brain from global cerebral ischemia", reperfusion injury by up-regulating endothelial nitric oxide synthase through the PI3K, Brain Res, pp.2012, 1445[DOI]
  7. Kim HM, "Neuroprotective strategies in neonatal hypoxic ischemic brain injury", J Japan Soc Premat Newb Med, 16, pp.123~133 (2004)
  8. Robertson NJ, "Which neuroprotective agents are ready for bench to bedside translation in the newborn infant?", J Pediatr, 160, pp.544~552 (2012)
  9. Filippi L, "Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI)", BMC Pediatr, 12, pp.144~ (2012)
  10. Wu YW, "Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics", Pediatrics, 130, pp.683~691 (2012)
  11. Sarkar S, "Does phenobarbital improve the effectiveness of therapeutic hypothermia in infants with hypoxicischemic encephalopathy?", J Perinatol, 32, pp.15~20 (2012)
  12. Chakkarapani E, "Xenon enhances hypothermic neuroprotection in asphyxiated newborn pigs", Ann Neurol, 68, pp.330~341 (2010)
  13. Faulkner S, "Xenon augmented hypothermia reduces early lactate", N-acetylaspartate and cell death in perinatal asphyxia, 2011, pp.70, 133~150
  14. Robertson NJ, "Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model", Brain, 136, pp.90~105 (2013)
  15. Jatana M, "Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats", Pediatr Res, 59, pp.684~689 (2006)
  16. Rajakumaraswamy N, "Neuroprotective interaction produced by xenon and dexmedetomidine on in vitro and in vivo neuronal injury models", Neurosci Lett, 409, pp.128~133 (2006)
  17. Hong IH, "Therapeutic effect of nimodipine in neonatal rat model of cerebral hypoxia-ischemia", J Korean Pediatr Soc, 42, pp.1552~1558 (1999)
  18. Levene MI, "The use of a calcium-channel blocker, nicardipine, for severely asphyxiated newborn infants", Dev Med Child Neurol, 32, pp.567~574 (1990)
  19. Nelson KB, "Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?", Pediatrics, 95, pp.263~269 (1995)
  20. Rouse DJ, "A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy", N Engl J Med, 359, pp.895~905 (2008)
  21. Levene M, "Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia", Arch Dis Child Fetal Neonatal Ed, 73, pp.F174~F177 (1995)
  22. Vohr BR, "School-age outcomes of very low birth weight infants in the indomethacin intraventricular hemorrhage prevention trial", Pediatrics, 111, pp.e340~e346 (2003)
  23. Aly H, "Ascorbic acid combined with ibuprofen in hypoxic ischemic encephalopathy: a randomized controlled trial", J Perinatol, 29, pp.438~443 (2009)
  24. Vásquez -Vivar J, "Tetrahydrobiopterin in the prevention of hypertonia in hypoxic fetal brain", Ann Neurol, 66, pp.323~331 (2009)
  25. Sato H, "Early replacement therapy in a first Japanese case with autosomal recessive guanosine triphosphate cyclohydrolase I deficiency with a novel point mutation", Brain Dev (2013)
  26. Bouslama M, "Melatonin prevents learning disorders in brain-lesioned newborn mice", Neuroscience, 150, pp.712~719 (2007)
  27. Alonso-Alconada D, "Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia", Histol Histopathol, 27, pp.771~783 (2012)
  28. Signorini C, "Free iron, total F-isoprostanes and total Fneuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin", J Pineal Res, 46, pp.148~154 (2009)
  29. Gitto E, "Effects of melatonin treatment in septic newborns", Pediatr Res, 50, pp.756~760 (2001)
  30. Chen YC, "Melatonin utility in neonates and children", J Formos Med Assoc, 111, pp.57~66 (2012)
  31. Gitto E, "Melatonin reduces oxidative stress in surgical neonates", J Pediatr Surg, 39, pp.184~189 (2004)
  32. Kelen D, "Experimental treatments for hypoxic ischaemic encephalopathy", Early Hum Dev, 86, pp.369~377 (2010)
  33. Torrance HL, "Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B", Pediatrics, 124, pp.350~357 (2009)
  34. Clancy RR, "Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest", Pediatrics, 108, pp.61~70 (2001)
  35. Kaandorp JJ, "Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study", BMC Pregnancy Childbirth, 10, pp.8~ (2010)
  36. Chaudhari T, "Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy", Cochrane Database Syst Rev, 7, pp.CD006817~ (2012)
  37. Kortsalioudaki C, "Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure", Liver Transpl, 14, pp.25~30 (2008)
  38. Whyte IM, "Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database", Curr Med Res Opin, 23, pp.2359~2368 (2007)
  39. Paintlia MK, "Nacetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain", J Neurosci Res, 78, pp.347~361 (2004)
  40. Ahola T, "N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial", J Pediatr, 143, pp.713~719 (2003)
  41. Probyn ME, "The anti-inflammatory agent N-acetyl cysteine exacerbates endotoxin-induced hypoxemia and hypotension and induces polycythemia in the ovine fetus", Neonatology, 98, pp.118~127 (2010)
  42. 장윤정, "Neuroprotection of Recombinant Human Erythropoietin Via Modulation of N-methyl-D-aspartate Receptors in Neonatal Rats with Hypoxic-ischemic Brain Injury", Neonatal medicine, 16(2), pp.221~233 (2009), 대한신생아학회
  43. 김행미, "편마비를 가진 뇌성마비 환아에서 확산 텐서강조영상을 Erythropoietin의 투여가 신생백서 저산소허혈뇌손상에 미치는 영향", Korean Journal of Pediatrics, 52(1), pp.105~110 (2009), 대한소아과학회
  44. Thomson Reuters Clinical Editorial Staff, "Neofax 2011" (2011), Thomson Reuters
  45. Elmahdy H, "Human recombinant erythropoietin in asphyxia neonatorum: pilot trial", Pediatrics, 125, pp.e1135~e1142 (2010)
  46. McAdams RM, "Outcomes of extremely low birth weight infants given early high-dose erythropoietin", J Perinatol, 33, pp.226~230 (2013)
  47. Zhu C, "Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy", Pediatrics, 124, pp.e218~e226 (2009)
  48. Andropoulos DB, "Erythropoietin neuroprotection in neonatal cardiac surgery: a phase I", II safety and efficacy trial, 2013, pp.146, 124~131
  49. Juul SE, "A phase I", II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety, 2008, pp.122, 383~391
  50. Shah N, "The effect of recombinant human erythropoietin on the development of retinopathy of prematurity", Am J Perinatol, 27, pp.67~71 (2010)
  51. Mehmet S, "One-year experience in the retinopathy of prematurity: frequency and risk factors, short-term results and follow-up", Int J Ophthalmol, 4, pp.634~640 (2011)
  52. Chen CM, "Conditions associated with hypertension in a high-risk premature infant", J Chin Med Assoc, 71, pp.485~490 (2008)
  53. Haiden N, "Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity", Thromb Haemost, 93, pp.118~123 (2005)
  54. Cariou A, "Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study", Resuscitation, 76, pp.397~404 (2008)
  55. Ehrenreich H, "Recombinant human erythropoietin in the treatment of acute ischemic stroke", Stroke, 40, pp.e647~e656 (2009)
  56. Schubert S, "Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets", Brain Res, 1058, pp.129~136 (2005)
  57. Liu Y, "Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats", Stroke, 35, pp.1460~1465 (2004)
  58. Filippi L, "Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy", Epilepsia, 50, pp.2355~2361 (2009)
  59. Glier C, "Therapeutic doses of topiramate are not toxic to the developing rat brain", Exp Neurol, 187, pp.403~409 (2004)
  60. Johannessen Landmark C, "Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy", CNS Drugs, 22, pp.27~47 (2008)
  61. Minamishima S, "Inhaled nitric oxide improves outcomes after successful cardiopulmonary resuscitation in mice", Circulation, 124, pp.1645~1653 (2011)
  62. Ben Abdennebi H, "How to protect liver graft with nitric oxide", World J Gastroenterol, 17, pp.2879~2889 (2011)
  63. Ballard RA, "Inhaled nitric oxide in preterm infants undergoing mechanical ventilation", N Engl J Med, 355, pp.343~353 (2006)
  64. Schreiber MD, "Inhaled nitric oxide in premature infants with the respiratory distress syndrome", N Engl J Med, 349, pp.2099~2107 (2003)
  65. Dworschak M, "Pharmacologic neuroprotection--is xenon the light at the end of the tunnel?", Crit Care Med, 36, pp.2477~2479 (2008)
  66. Coburn M, "Randomized controlled trial of the haemodynamic and recovery effects of xenon or propofol anaesthesia", Br J Anaesth, 94, pp.198~202 (2005)
  67. Preckel B, "Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function", Br J Anaesth, 88, pp.264~269 (2002)
  68. Ma D, "Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia", Ann Neurol, 58, pp.182~193 (2005)
  69. Martin JL, "Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat", Br J Anaesth, 98, pp.236~240 (2007)
  70. Paris A, "The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype", Anesth Analg, 102, pp.456~461 (2006)
  71. Afonso J, "Dexmedetomidine: current role in anesthesia and intensive care", Rev Bras Anestesiol, 62, pp.118~133 (2012)
  72. Gupta P, "Safety and efficacy of prolonged dexmedetomidine use in critically ill children with heart disease*", Pediatr Crit Care Med, 13, pp.660~666 (2012)
  73. Perrone S, "Effects of lutein on oxidative stress in the term newborn: a pilot study", Neonatology, 97, pp.36~40 (2010)
  74. Lampl Y, "Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin", Clin Neuropharmacol, 33, pp.129~134 (2010)
  75. Patti G, "Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study", J Am Coll Cardiol, 61, pp.1379~1387 (2013)
  76. Sierra S, "Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death", J Alzheimers Dis, 23, pp.307~318 (2011)
  77. Li A, "Simvastatin attenuates hypomyelination induced by hypoxia-ischemia in neonatal rats", Neurol Res, 32, pp.945~952 (2010)
  78. Papazisis G, "Deferoxamine decreases the excitatory amino acid levels and improves the histological outcome in the hippocampus of neonatal rats after hypoxia-ischemia", Pharmacol Res, 57, pp.73~78 (2008)
  79. Liachenko S, "Deferoxamine improves early postresuscitation reperfusion after prolonged cardiac arrest in rats", J Cereb Blood Flow Metab, 23, pp.574~581 (2003)
  80. Zhou Y, "Isoflurane posttreatment reduces neonatal hypoxic-ischemic brain injury in rats by the sphingosine-1-phosphate", phosphatidylinositol-3-kinase, Stroke, pp.2010, 41[DOI]
  81. Gidday JM, "Nitric oxide mediates cerebral ischemic tolerance in a neonatal rat model of hypoxic preconditioning", J Cereb Blood Flow Metab, 19, pp.331~340 (1999)
  82. Tsuji M, "Protective effect of aminoguanidine on hypoxic-ischemic brain damage and temporal profile of brain nitric oxide in neonatal rat", Pediatr Res, 47, pp.79~83 (2000)
  83. Nijboer CH, "Gender-specific neuroprotection by 2-iminobiotin after hypoxia-ischemia in the neonatal rat via a nitric oxide independent pathway", J Cereb Blood Flow Metab, 27, pp.282~292 (2007)
  84. Bonfils PK, "Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia", Neurochem Int, 49, pp.508~518 (2006)
  85. Lin S, "IGF-1 protects oligodendrocyte progenitor cells and improves neurological functions following cerebral hypoxia-ischemia in the neonatal rat", Brain Res, 1063, pp.15~26 (2005)
  86. Zheng XR, "Neuroprotection of VEGF-expression neural stem cells in neonatal cerebral palsy rats", Behav Brain Res, 230, pp.108~115 (2012)
  87. Kwan SL, "Therapeutic effect of transforming growth factor (TGF)-β1 in neonatal rat model of hypoxic-ischemic brain damage", J Korean Soc Neonatol, 7, pp.154~160 (2000)
  88. Scafidi S, "Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain", Dev Neurosci, 32, pp.480~487 (2010)
  89. Yu Jin Kim, "Neuroprotective effects of L-carnitine against oxygenglucose deprivation in rat primary cortical neurons", Korean Journal of Pediatrics, 55(7), pp.238~248 (2012), 대한소아과학회
  90. 박창로, "신생쥐의 저산소성 허혈성 뇌손상에서 손상 후 덱사메타손의 투여 효과", Korean Journal of Pediatrics, 46(10), pp.989~995 (2003), 대한소아과학회
  91. van den Broek MP, "Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach", Clin Pharmacokinet, 51, pp.671~679 (2012)

관련 논문AI추천

신생아 저산소성 허혈성 뇌증의 저체온 치료장미영대한신생아학회 · Neonatal medicine2013 · 제20권 제1호Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy in Newborn Infants성인경대한신생아학회 · Neonatal medicine2017 · 제24권 제4호열 전처지가 신생쥐의 허혈성 저산소성 뇌손상에 미치는 영향곽수희, 권순학, 김행미, 손윤경, 오기원, 이경희, 임해리, 최병호대한신생아학회 · Neonatal medicine2008 · 제15권 제1호Erythropoietin Reduces Death and Neurodevelopmental Impairment in Neonatal Hypoxic-Ischemic Encephalopathy이주영, 전가원, Bang Seung Jun, Jun Yong Hoon대한신생아학회 · Neonatal medicine2022 · 제29권 제4호저산소-허혈성 뇌병증 환자의 신경학적 회복 예측김용욱, 김제경, 윤서연대한뇌신경재활학회 · 뇌신경재활2014 · 제7권 제1호신생아 경련성 질환의 항경련제 요법유재은대한신생아학회 · Neonatal medicine2009 · 제16권 제1호

이 간행물의 다른 논문 (17건)

대한신생아학회 창립 20주년을 기념하며남궁란pp. 233-233한국에서 신생아 집중치료 역사의 이정표최중환pp. 234-246한국 신생아역학 최근 30년간의 변화최용성, 배종우, 정성훈pp. 247-255초미숙아 생존 한계 극복 방안장윤실, 박원순pp. 256-265빌리루빈 대사와 빌리루빈 뇌증이철, 이순민, 남궁란pp. 266-273
원문 보기